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Abstract 
We measured the effects of combinations of verapamil, vinblastine, mefloquine, and tamoxifen, all being modulators of 
the multidrug resistance pump, P-glycoprotein, on the accumulation of labelled daunomycin i to multidrug-resistant P388 
leukemia cells at 37°C. We found that, contrary to our initial expectations (based on Ayesh, Shao and Stein (1996) Biochim. 
Biophys. Acta 1316, 8), vinblastine, mefloquine, and tamoxifen all appeared to interact with one another synergistically, i.e. 
by the kinetics of a non-competitive interaction. A simple kinetic analysis howed that pairs of co-operating modulators can 
give apparent non-competitive behaviour, but refined kinetic analysis enables the two types of interaction to be 
distinguished. The modulators vinblastine, mefloquine, and tamoxifen thus appear to co-operate with one another in pairs to 
bring about reversal of P-glycoprotein. This may have important implications for the design of new modulators of 
P-glycoprotein. 
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1. Introduction 
P-Glycoprotein, the product of the MDR1 gene, is 
an important contributor to multidrug resistance in 
many cell types [1,2] and has been found to be 
expressed in a substantial number of tumors [3-8]. 
P-glycoprotein acts by pumping out its drug substrate 
from within the tumor cell, reducing the effectiveness 
of the chemotherapeutic agent that is being adminis- 
tered. It is an ATPase [9-11] whose activity is en- 
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hanced by the presence of numerous ubstrates and 
substrate analogues. A very wide range of substrates 
are pumped out of cells by P-glycoprotein [12]. 
Researchers have sought clinically-useful reversers of 
P-glycoprotein, that block its action, and lead to the 
accumulation of drugs within erstwhile resistant cells. 
Many such reversers have been identified [13] and 
have been characterised kinetically in terms of their 
affinity for P-glycoprotein [14]. The first generation 
of reversers of P-glycoprotein, drugs such as vera- 
pamil [15], cyclosporin A [16], quinidine [17], and 
amiodarone [18] have not proved very useful in the 
clinic. In the effort to find more effective reversers, 
structure/activity relationships that determine the ef- 
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fectiveness of reversers have been searched for [19- 
21]. A number of second-generation reversers are 
now in clinical trial. These reversers (also termed 
modulators) include the cyclosporin A analogue PSC 
833 [22,23], developed by Sandoz, the acridonecar- 
boximide GF120918 [24], developed by Glaxo, 
Servier's $9788 [25,26], a triazinoaminopiperidine 
derivative, and the R-isomer of verapamil, dexvera- 
pamil [27], developed by Knoll. Continued evelop- 
ment of new reversers is a necessity in improving 
cancer remission rates. Secure knowledge of the 
structural basis for the differential binding of sub- 
strates and reversers i  the basis for further advances 
in designing new and more effective reversers. 
Kinetic analysis has indicated that certain reversers 
interact in a synergistic (non-competitive) fashion 
with cytotoxin substrates [28-30] and it has been 
therefore suggested that substrates and reversers of 
P-glycoprotein bind to distinct, non-overlapping re- 
gions of the molecule. In addition, it has been shown 
that good substrates are poor reversers and good 
reversers poor substrates (S. Scala, S.E. Bates, W.D. 
Stein et al., submitted for publication), a finding 
which, if confirmed, could lead to a more informed 
search for reversers. It has been proposed that pairs 
of reversers can interact synergistically in blocking 
cytotoxin pumping by P-glycoprotein [31-33], or in 
modulating its action as an ATPase [34]. In a previ- 
ous study [30], we showed that detailed kinetic analy- 
sis of cytotoxin accumulation data enabled a distinc- 
tion to be made between reversers that, between 
themselves, interact ogether in additive, synergistic 
or co-operative fashion. These results suggested a
model in which P-glycoprotein possesses two dis- 
tinct sites for modulators. Vinblastine, mefloquine, 
and tamoxifen bind to one site, while verapamil, 
quinidine and certain other reversers are bound to a 
second site. A prediction of this model is that vinblas- 
tine, tamoxifen and mefloquine should interact addi- 
tively with one another on the site to which all three 
bind. In the present paper we present he results of a 
test of this prediction. Contrary to our original hy- 
pothesis, we found that the three reversers interacted 
synergistically. Deeper analysis showed, however, 
that this behaviour arose from mutual, co-operative 
interactions between the three reversers. We show 
how such synergism, based on co-operative interac- 
tions between reversers, can be identified. Our data 
may have important implications for the design of 
new reversers of P-glycoprotein. 
2. Materials and methods 
These were mainly as in the previous paper [30]. 
In brief, the cells used are a drug-resistant s rain of 
P388 lymphoma cells, a kind gift from Prof Avner 
Ramu of the Hadassah-Hebrew University Hospital 
[35,36]. These cells have been shown [30] to have 
essentially the same kinetic characteristics a  P388 
cells that have been transfected with authentic P- 
glycoprotein. The cells are grown in RPMI 1640 
medium to which is added penicillin, streptomycin, 
amphotericin, /3-mercaptoethanol, and 1.0% (w/v)  
glutamate, together with 10% foetal calf serum, in 
5% CO2/humidified air at 37°C, in suspension cul- 
ture. 0.4 ml of a suspension of cells in complete 
RPMI are transferred to a microfuge tube, and 40 /zl 
of a solution of 3H-labelled cytotoxin, sufficient o 
give a final concentration of daunomycin at 2 nM, 
and containing the required concentration f reverser, 
added at zero time. Uptake of the cytotoxin is stopped 
by rapid centrifugation, the supernatant layer immedi- 
ately quantitatively removed by aspiration, and the 
cell pellet resuspended in 0.5 ml 10% Triton X-100. 
The cell suspension is transferred to vials for liquid 
scintillation counting. In all cases, aliquots of cells 
are incubated for comparable times with no reverser 
present, and zero time uptakes performed by adding 
appropriate aliquots of pre-cooled labelled dauno- 
mycin solutions to pre-cooled cell suspensions. The 
latter determination measures the amount of label 
trapped between the cells during centrifugation. 
Aliquots of the loading solutions are taken for scintil- 
lation counting to enable the conversion of the data 
from dpm per sample to pmoles of cytotoxin accumu- 
lated per million cells. 
2.1. Data analysis 
We define a Michaelis parameter, Ki, as the in- 
trinsic binding parameter of the reverser. This is the 
concentration of a reverser at which the amount of 
free P-glycoprotein is equal to the amount bound to 
that reverser. To obtain the appropriate values of this 
parameter, K~, for a reverser which blocks P-glyco- 
protein's action on the accumulation of daunomycin, 
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we used Eq. (A-4) of the Appendix in [30]. We 
reproduce that equation here as: 
C 
D i = D O + (D~ - Do). (1) 
K i " (D~/Do)  + C 
This equation gives the dependence of the intra- 
cellular concentration of cytotoxin, D i, at any con- 
centration C of a reverser on the value of K i for that 
reverser. D o is the accumulation i the absence of 
reverser, D~ the acumulation at an infinitely high 
reverser concentrations. D o, D=, and K i are found by 
curve-fitting from the amount of accumulation Di as 
a function of C. 
The parallel Eq. (A-7) and Eq. (A-8) in [30] 
describe the effects of pairs of reversers in terms of 
the above variables and of the concentration of the 
second reverser, B. We reproduce these here as Eqs. 
(2) and (3). 
Where the second reverser is additive, i.e. acts 
according to the competition model of the enzymolo- 
gist [37], we have 
Di 
- -  = D O + (D~ - Do)"  
De 
C 
K iK( I+B)+C 
(2) 
Thus, the effect of a competititive reverser is to 
increase the apparent K i by the factor (1 + B), where 
B is the concentration f the second reverser, divided 
by its intrinsic K i. For the case of a synergistic 
second reverser, i.e., one that acts with non-competi- 
tive kinetics [37], we obtain: 
C 
D i = D O + (D~ - Do). D~ (3) 
K i D---~o + C 
where the value of D o is reduced by the presence of 
the second, synergistic reverser, but no other change 
appears in the formalism. It will be seen that the 
effect of a second, synergistic reverser on cytotoxin 
accumulation is to leave the computed value of the 
intrinsic K i unchanged. By fitting these equations to 
the data of D i against C, at any value of B, using 
standard curve-fitting procedures, the appropriate val- 
ues of K i, D o , and D~ can be found. From the 
dependence of this computed value of K i (which 
refers to C) on the concentration of the second 
inhibitor, B, one can test whether the interaction 
between the two reversers i  additive (when K i will 
increase with [B]) or synergistic (when K i will 
remain unchanged). In the former case, one can find 
the appropriate value of Ki for the second reverser. 
3.  Resu l ts  
Fig. 1A shows the effect of increasing mefloquine 
concentrations on the accumulation of daunomycin at 
2 nM during 60 min at 37°C, at four vinblastine 
concentrations ranging from 0 to 2 /xM. From each 
curve we computed the intrinsic K~ for mefloquine 
acting as a reverser of the MDR pump, using Eq. (1) 
(see Section 2). The figure is representative of three 
similar experiments. The means of these derived K~ 
values (±S.E.) are plotted against the vinblastine 
concentrations in Fig. lB. The K i slightly decreases 
with increasing vinblastine concentrations. The solid 
line is the regression of K i on  [vinblastine] and has 
negative slope equal to 0.045 (/xM)-1, and regres- 
sion coefficient of 0.896. We were surprised to find 
this result. We had shown [30] that both these re- 
versers acted synergistically, i.e., as non-competitors, 
against verapamil. We had assumed, therefore, that 
they would be themselves in a single family, and thus 
compete with one another. To explore this phe- 
nomenon further, we decided also to determine the 
mutual effects of mefloquine and tamoxifen. 
Thus, Fig. 2A shows strictly comparable xperi- 
ments on the effect of increasing mefloquine concen- 
trations at four tamoxifen concentrations ranging from 
0 to 8 /xM. Again, from each curve we computed the 
intrinsic K i for mefloquine acting as a reverser, and 
plotted these K i values against he tamoxifen concen- 
trations in Fig. 2B. These points represent the means 
+ S.E. of six independent experiments. Again, the K i 
slightly decreases with increasing tamoxifen concen- 
trations. The regression of K i on [tamoxifen] has a 
non-significant egative slope of 0.011 (/xM)- 1, and 
regression coefficient of 0.471. Thus, for both of 
these reversers we find, apparently, synergistic inter- 
actions with mefloquine. If synergism implies that the 
reversers act at physically different sites on P-glyco- 
protein, these results would suggest hat there are at 
least four separate reverser-binding sites on the pro- 
tein, one for the family that includes verapamil and 
one each for vinblastine, tamoxifen and mefloquine. 
A more reasonable hypothesis to account for our 
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Fig. 1. Effect of mefloquine on accumulation of daunomycin at 2 nM by P388 lymphoma cells, both in the presence and absence of 
vinblastine. In (A), cells were incubated for 1 h at 37°C with a series of mefloquine concentrations (0, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 
p,M), containing different concentrations of vinblastine: O-©,  0, Q-O,  0.5, v -v ,  1.0, and T -v  2 /xM. The points are means of 
duplicates. In (B), the calculated values of K i (see text) for mefloquine, means + S.E. for 3 determinations each performed as in (A), are 
plotted against relevant vinblastine concentrations. 
findings would be that pairs of reversers could be- 
have co-operatively in bringing about reversal of 
P-glycoprotein. We had reported that some reversers 
of P-glycoprotein behaved co-operatively within a 
single reverser species [30], i.e. that their ability to 
reverse P-glycoprotein depended on their concentra- 
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Fig. 2. Effect of mefloquine on accumulation of daunomycin at 2 nM by P388 lymphoma cells, both in the presence and absence of 
tamoxifen. In (A), cells were incubated for 1 h at 37°C with a series of mefloquine concentrations (0, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 
/xM), containing different concentrations of tamoxifen: O-Q,  0, O-Q,  2, v -v ,  4, and v -v  8 /xM. The points are means of 
duplicates. In (B), the calculated values of K i (see text) for mefloquine, means + S.E. for 6 determinations each performed as in (A), are 
plotted against relevant tamoxifen concentrations. 
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don with a Hill number [37] of around 2. Would pairs 
composed of different reverser molecules interact 
co-operatively? 
We first had to confirm that tamoxifen and meflo- 
quine were among the family of reversers that indeed 
act co-operatively. Fig. 3 shows, on a semi-logarith- 
mic scale, how the extent of daunomycin accumula- 
tion in our drug-resistant P388/ADR cells is in- 
creased by increasing concentrations of the modulator 
tamoxifen (Fig. 3A) or mefloquine (Fig. 3B). The 
data are the means ___ spread of two independent ex- 
periments each performed in duplicate. The solid line 
in both Fig. 3A and Fig. 3B is the prediction of the 
case where the pump binds to, and is blocked by, 
single molecules of the reverser (see [30], as given by 
Eq. (1) in Section 2). The dashed line is for the case 
where more than one molecule of the reverser is 
needed to provide effective blocking of the pump, 
i.e., where we use this same Eq. (1) but insert a Hill 
number of n as the index to which the concentration 
of the reverser is raised in the curve-fitting. Clearly, 
pairs of tamoxifen or mefloquine molecules are 
needed to block P-glycoprotein. We applied a statis- 
tical analysis to these curve-fits. Our curve-fitting 
• program gives us the variance remaining between the 
data and the best curve fit, i.e., the sum of the squares 
of the deviations between the data points and the 
curve-fit. We calculate the ratio between the variance 
left, after curve fitting, using a Hill number of 1 to 
that left using a Hill number of n. Entering Table A 
14 of Snedecor and Cochran [38] for the distribution 
of the statistical parameter F enables us to reject one 
or other of these models. Both for tamoxifen and for 
mefloquine, the model with Hill number of n is 
preferable with a significance of P < 0.05. The best- 
fit Hill number was found to be 2.13 +0.30 for 
tamoxifen and 1.74 + 0.18 for mefloquine. In our 
previous paper [30], the data for vinblastine were 
depicted. For this reverser/substrate, thebest-fit Hill 
number was 1.81 + 0.13. It would appear that at least 
pairs of all these three reverser molecules are needed 
to provide effective blocking of the pump's action. 
It is a simple matter to derive a mathematical 
formalism that describes the behaviour of two re- 
versers that co-operate with each other in bringing 
about reversal. Consider, first, a transport pump that 
is blocked by a reverser, with simple Michaelis- 
Menten kinetics. If we write D~ for the residual 
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Fig. 3. Effect of two modulators of the P-glycoprotein on accumulation f daunomycin at2 nM by P388 leukemia cells, incubated for 1 h 
at 37°C. (A) tamoxifen, (B) mefloquine. The solid line in each figure is the best-fit curve fit to the accumulation equation (Eq. (1) of 
Section 2) with a Hill number of 1, the dashed line with the best-fit Hill number (2.1, with K i = 1.1 /xM, for tamoxifen; 1.7, with 
K i = 0.41 /zM, for mefloquine). For both (A) and (B) each point is the mean (+spread) of two experiments, each done in triplicate. 
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activity of the pump at any concentration C of re- 
verser, D o for the activity in the absence of reverser, 
D~ for that at infinitely high concentrations of re- 
verser, and g i for the inhibition constant for that 
reverser, we have: 
C 
D i = D O + (D~ - D o).  - -  (4) 
Ki -I- C 
From this equation, D 0, D=, and K i are, of course, 
found from the extent of residual activity D i as a 
function of C. This equation is the basis of the 
curve-fitting used in Figs. 1 and 2 (see Section 2, and 
[30]). For a reverser that acts with a Hill number of 2, 
i.e., for which pairs of reverser molecules are needed 
to give reversal we have: 
C 2 
D i = D o + (D~ - Do)" Ki + C-------- ~ (5) 
It is this equation, after taking into account the 
effect of the pump on reducing the internal concentra- 
tion of cytotoxin [14], that was used to curve-fit Fig. 
3A and Fig. 3B. Now, if there are two reversers, one 
present at concentration C and the other at concentra- 
tion B, and we assume that they can co-operate so 
that all the forms CC, BB, and CB (and BC) are 
active in blocking the pump, we can simply replace 
the term C in Eq. (2) by the sum C + B, giving, 
(C + B) 2 
D i = D O + (D= - O0) .  (6 )  
g i + (C  + B)  2 
This equation was used to generate theoretical 
curves for the interaction between two reversers that 
co-operate in pairs to bring about reversal. Fig. 4A 
depicts the results of a simulation of the effect of two 
such co-operating reversers. The concentration of the 
first reverser is varied continually and is given on the 
abscissa of the plot. The concentration of the second 
reverser is increased in three steps, from 0 to 0.4 to 
0.8 and to 1.6 multiples of its inhibition constant K i. 
Even at zero concentration of the first reverser, addi- 
tion of increasing concentrations of the second re- 
verser blocks the activity of the pump, raising the 
computed extent of accumulation of the cytotoxin. 
Visual inspection of the four curves suggests that the 
Hill number is reduced as the concentration of the 
second reverser is increased. Indeed, curve-fitting the 
data, using Eq. (5) modified so that a Hill number of 
n is used rather than the fixed value 2, shows that the 
Hill number drops from 2 through 1.91, 1.24 to 1.13 
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Fig. 4. Theoretical plot and replot for the effect of pairs of co-operating modulators on the accumulation of a cytotoxin in drug-resistant 
cells. In (A), the concentration of the variable modulator ranges from 0 to 10 x its K i while that of the fixed modulator is set at 0, 0.4, 
0.8 or 1.6 X the value of its K i. (B) is a replot of the value of K i of the variable modulator at each of the four concentrations of the fixed 
modulator, as derived by curve-fitting of Eq. (1) to the theoretical curves of the main figures. 
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as the concentration of the second reverser is raised. 
We used Eq. (4), the simple Michaelis-Menten form, 
to curve-fit he simulated ata of Fig. 4A, thus mim- 
icking the procedure we used with experimental data 
in Figs. 1 and 2. We thus obtained apparent K i 
values for the effect of the first (variable) reverser on 
the pump, at each value of the concentration of the 
second reverser. The analysis yields the 'data' given 
as Fig. 4B, where the apparent K i is plotted against 
the concentration of the second reverser. Clearly, the 
apparent g i does not rise steadily with concentration, 
as would be the case for an additive (i.e., competi- 
tive) interaction, but rather remains more or less 
constant or even falls somewhat, recalling the be- 
haviour of a non-competitor, and even more strongly, 
recalling the data in Figs. 1 and 2. 
The drop in Hill number, found as one increases 
the concentration of a second reverser, was used as a 
test for distinguishing between true synergism and 
the type of synergism that is displayed between two 
co-operating reversers. Fig. 5A shows simulated plots 
of pump activity against concentration of first re- 
verser for four different cases: the solid line when 
only the first reverser is present; the dotted line 
where a second, competitive reverser is added: the 
dashed line where the second reverser is a true 
non-competitor (in the sense of the enzymologist): 
the dotted/dashed line, where this second reverser is 
a co-operator. For both the first two cases where a 
second reverser is present, it is clear that the pre- 
dicted activity/concentration curve is sigmoidal. For 
the 'co-operator', the sigmoidicity is greatly reduced. 
The computed values of the inhibition constants K i 
are: 1, 1, 2 and 0.77; and Hill numbers n: 2, 2, 2 and 
1.24, for the cases of no second reverser, a non-com- 
petitor, a competitor, and a co-operator, espectively. 
Thus, only for a co-operating reverser does the de- 
rived Hill number fall. In contrast, for the competitor, 
K~ rises while for the non-competitor it remains 
constant. This, then, is the required test for the 
presence of a co-operating second reverser: when it is 
added to a first reverser, the Hill number obtained for 
the dependence of activity on the concentration of the 
first reverser should fall below 2, while the derived 
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tamoxifen, at 6 /xM. 
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K~ should not increase. Fig. 5B depicts data (means 
+ S.E. of triplicates) obtained in an experiment in 
which, in both cases, vinblastine was the first re- 
verser of daunomycin accumulation while the second 
reverser was either verapamil (solid circle) or tamox- 
ifen (open triangles). The plot for verapamil appears 
sigmoidal, while that for tamoxifen is not. Curve-fit- 
ting the data using Eq. (1) of Section 2 gave a value 
of 1.82 for the data for verapamil and 1.40 for the 
tamoxifen data, confirming the visual conclusion. In 
five similar experiments, the Hill number found by 
curve-fitting the data for tamoxifen was always sub- 
stantially lower than that found for verapamil as the 
second reverser. 
4. Conclusions 
We had reported [30] that vinblastine blocks the 
action of P-glycoprotein on daunomycin with a steep 
concentration dependence, suggesting that pairs of 
vinblastine molecules interact with P-glycoprotein. 
We now extend this finding and show that the rever- 
sal kinetics for mefloquine and tamoxifen also dis- 
play a Hill number closer to 2, suggesting that these 
molecules, too, interact in pairs to block P-glyco- 
protein. In addition, we show that the effects of 
mefloquine on the reversal kinetics of vinblastine and 
tamoxifen are consistent with a model in which vin- 
blastine and mefloquine, or tamoxifen and meflo- 
quine, interact with each other in pairs to block 
P-glycoprotein. Thus, these reversers appear to be- 
have synergistically towards each other. We develop 
a kinetic test whereby this 'synergism' (where the 
two different ligands can replace each other at the 
ligand-binding site of the receptor) can be distin- 
guished from true synergism - where two ligands 
bind at quite different sites. 
This result has important implications for the use 
of P-glycoprotein blockers and for the future design 
of new, better blockers. First, two reversers, each of 
which when present as a single species behaves 
co-operatively, can co-operate with each other and 
interact synergistically. Reversal can, therefore, be 
achieved with a combination drug approach, at lower 
doses for each reverser than would be needed for 
each present separately. If the drugs act, in their 
side-effects, on different target organs in the body, 
such side-effects will be minimised when thetwo 
drugs are given simultaneously: They will have syn- 
ergistic effects on P-glycoprotein but different and 
perhaps non-additive side-effects. Second, the fact 
that such individual reversers act in pairs at the active 
center of P-glycoprotein implies that it might be 
possible to design a reverser which is itself made of 
two reverser molecules already joined together cova- 
lently. Such a newly-synthesised reverser would be 
expected to bind with far greater affinity to P-glyco- 
protein than would the component half-duplexes. The 
permanent complex would bind simultaneously to the 
two sites to which single reverser molecules bind, 
enhancing its affinity by the entropic effect (as found 
when chelators bind their ligands). It may be that 
some of the already studied reversers (such as cy- 
closporin A which has a particularly high affinity for 
P-glycoprotein) straddle both sites to which single 
reverser molecules bind. Investigating this possibility 
might lead to new insights and new approaches to 
reverser design. 
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